eligibility_summary
Adults ≥18 with advanced solid tumors lacking options or NHL relapsed/refractory ≥2 lines, measurable disease (RECIST/Lugano), ECOG 0–2, tumor tissue, life expectancy ≥12 wks. Exclude: HCB101 allergy, active/untreated CNS mets/meningitis, surgery/RT/radioisotope <2 wks, significant CV disease, unresolved >G1 AEs, bleeding disorder/recent RBC transfusion, recent hemolysis/Evans, concurrent systemic therapy, warfarin/herbals, prior CD47/SIRPα, other malignancy ≤2 yrs, recent trial/device, HBV/HCV/HIV/TB, substance abuse.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05892718 tests HCB101, an IV SIRPα‑Fc fusion protein (biologic immunotherapy). Mechanism: the SIRPα domain acts as a decoy to bind CD47 on tumor cells, blocking the CD47–SIRPα “don’t‑eat‑me” checkpoint and restoring macrophage-mediated phagocytosis (ADCP). Its Fc region can engage Fcγ receptors to enhance myeloid effector functions and promote dendritic cell antigen presentation, supporting downstream T‑cell priming. Targets: CD47 on tumor cells, SIRPα on macrophages/monocytes/dendritic cells, the myeloid innate immune checkpoint pathway (CD47–SIRPα) and associated SHP‑1/2 inhibitory signaling.